June 17, 2024, Boston, MA: The AMR Action Fund announced this week that it has invested in Elion Therapeutics, a biotechnology company dedicated to transforming the treatment of life-threatening invasive fungal infections (IFIs).
"With resistance to existing antifungals growing and infection rates increasing, it is essential that we develop effective therapies for patients in need," said AMR Action Fund CEO Henry Skinner, PhD. "The World Health Organization recently identified four fungal pathogens that it considers a 'critical priority,' including Aspergillus fumigatus. We are pleased to support the team at Elion and believe their work could deliver an important treatment for patients suffering from devastating fungal infections."
Learn more.
